• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管选择和血管生成拟态介导了对血管生成抑制策略的抵抗。

Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies.

机构信息

Nuffield Division of Laboratory Science, Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.

Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy.

出版信息

Cancer Rep (Hoboken). 2022 Dec;5(12):e1318. doi: 10.1002/cnr2.1318. Epub 2020 Dec 9.

DOI:10.1002/cnr2.1318
PMID:33295149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9780428/
Abstract

BACKGROUND

The concept that all the tumors need the formation of new vessels to grow inspired the hypothesis that inhibition of angiogenesis would have led to "cure" cancer. The expectancy that this type of therapy would have avoided the insurgence of resistance was based on the concept that targeting normal vessels, instead of the cancer cells which easily develop new mutations, would have allowed evasion of drug caused selection is, however, more complex as it was made apparent by the discovery of nonangiogenic tumors. At the same time an increasing number of trials with antiangiogenic drugs were coming out as not as successful as expected, mostly because of the appearance of unexpected resistance.

RECENT FINDINGS

Among the several different mechanisms of resistance to antiangiogenic treatment by now described, we review the evidences that vascular co-option and vasculogenic mimicry by nonangiogenic tumors are effectively two of such mechanisms. We focused on reviewing exclusively the study, both clinical and preclinical, that offer a demonstration that vascular co-option and vasculogenic mimicry are effectively two mechanisms of both intrinsic and acquired resistance.

CONCLUSION

The discovery that vascular co-opting and vasculogenic mimicry are two ways of escaping antiangiogenic treatment, prompts the need for a better understanding of this phenomenon in order to improve cancer treatment.

摘要

背景

所有肿瘤都需要新血管形成才能生长的观点启发了这样一种假设,即抑制血管生成将导致“治愈”癌症。这种治疗方法有望避免耐药性的产生,其依据是靶向正常血管(而不是容易产生新突变的癌细胞)将避免药物选择导致的逃逸,然而,随着非血管生成肿瘤的发现,这种情况变得更加复杂。与此同时,越来越多的抗血管生成药物试验并没有像预期的那样成功,主要是因为出现了意想不到的耐药性。

最近的发现

在目前描述的几种不同的抗血管生成治疗耐药机制中,我们回顾了证据,表明血管选择和非血管生成肿瘤的血管生成模拟实际上是其中两种机制。我们专门重点回顾了仅提供证据表明血管选择和血管生成模拟实际上是内在和获得性耐药的两种机制的临床前和临床研究。

结论

发现血管选择和血管生成模拟是逃避抗血管生成治疗的两种方式,这促使人们需要更好地了解这一现象,以改善癌症治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e07/9780428/def7929a9621/CNR2-5-e1318-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e07/9780428/7fa2fbbca7d1/CNR2-5-e1318-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e07/9780428/c1412face32a/CNR2-5-e1318-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e07/9780428/def7929a9621/CNR2-5-e1318-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e07/9780428/7fa2fbbca7d1/CNR2-5-e1318-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e07/9780428/c1412face32a/CNR2-5-e1318-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e07/9780428/def7929a9621/CNR2-5-e1318-g003.jpg

相似文献

1
Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies.血管选择和血管生成拟态介导了对血管生成抑制策略的抵抗。
Cancer Rep (Hoboken). 2022 Dec;5(12):e1318. doi: 10.1002/cnr2.1318. Epub 2020 Dec 9.
2
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells.逃避抗血管生成治疗:癌细胞采用的策略
Int J Mol Sci. 2016 Sep 6;17(9):1489. doi: 10.3390/ijms17091489.
3
The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers.环状RNA在血管共选和血管生成拟态中的新作用:癌症抗血管生成治疗的临床见解
Cancer Metastasis Rev. 2022 Mar;41(1):173-191. doi: 10.1007/s10555-021-10000-8. Epub 2021 Oct 18.
4
Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis.肿瘤细胞介导的新生血管形成和淋巴管生成促进肿瘤进展和癌症转移。
Biochim Biophys Acta. 2013 Dec;1836(2):273-86. doi: 10.1016/j.bbcan.2013.08.001. Epub 2013 Aug 8.
5
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.癌症抗血管生成治疗耐药的新见解:机制与治疗方面。
Drug Resist Updat. 2022 Sep;64:100849. doi: 10.1016/j.drup.2022.100849. Epub 2022 Jun 30.
6
Brucine Suppresses Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cell Line MDA-MB-231.苦马豆素抑制人三阴性乳腺癌 MDA-MB-231 细胞系的血管生成拟态。
Biomed Res Int. 2019 Jan 6;2019:6543230. doi: 10.1155/2019/6543230. eCollection 2019.
7
Pro-angiogenic activity and vasculogenic mimicry in the tumor microenvironment by leptin in cancer.肿瘤微环境中瘦素促进血管生成活性和血管生成拟态在癌症中的作用。
Cytokine Growth Factor Rev. 2021 Dec;62:23-41. doi: 10.1016/j.cytogfr.2021.10.006. Epub 2021 Oct 23.
8
Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.缺氧肿瘤微环境中的血管生成拟态机制。
Mol Cancer. 2021 Jan 4;20(1):7. doi: 10.1186/s12943-020-01288-1.
9
Vascular co-option in resistance to anti-angiogenic therapy.抗血管生成治疗耐药中的血管共选择
Front Oncol. 2023 Dec 11;13:1323350. doi: 10.3389/fonc.2023.1323350. eCollection 2023.
10
Dehydroeffusol effectively inhibits human gastric cancer cell-mediated vasculogenic mimicry with low toxicity.去氢土荆皮乙酸以低毒性有效抑制人胃癌细胞介导的血管生成拟态。
Toxicol Appl Pharmacol. 2015 Sep 1;287(2):98-110. doi: 10.1016/j.taap.2015.05.003. Epub 2015 May 14.

引用本文的文献

1
An updated review deciphering the anticancer potential of pentacyclic triterpene lupeol and its nanoformulations.一篇关于解读五环三萜羽扇豆醇及其纳米制剂抗癌潜力的最新综述。
Front Pharmacol. 2025 May 9;16:1594901. doi: 10.3389/fphar.2025.1594901. eCollection 2025.
2
LncRNAs Regulate Vasculogenic Mimicry in Human Cancers.长链非编码RNA在人类癌症中调控血管生成拟态
Cells. 2025 Apr 20;14(8):616. doi: 10.3390/cells14080616.
3
Understanding Neovascularization in Glioblastoma: Insights from the Current Literature.了解胶质母细胞瘤中的新生血管形成:来自当前文献的见解。

本文引用的文献

1
Mechanisms of resistance to anti-angiogenic treatments.抗血管生成治疗的耐药机制。
Cancer Drug Resist. 2019 Sep 19;2(3):595-607. doi: 10.20517/cdr.2019.39. eCollection 2019.
2
Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma.三维组织学、免疫组织化学和多重免疫荧光分析肺腺癌中空气传播途径中血管共选择的动态变化。
J Thorac Oncol. 2020 Apr;15(4):589-600. doi: 10.1016/j.jtho.2019.12.112. Epub 2019 Dec 27.
3
Prediction of Histopathologic Growth Patterns of Colorectal Liver Metastases with a Noninvasive Imaging Method.
Int J Mol Sci. 2025 Mar 19;26(6):2763. doi: 10.3390/ijms26062763.
4
Microfluidic model of the alternative vasculature in neuroblastoma.神经母细胞瘤中替代脉管系统的微流控模型
In Vitro Model. 2024 Jan 15;3(1):49-63. doi: 10.1007/s44164-023-00064-x. eCollection 2024 Feb.
5
The role of N6-methyladenosine modification in tumor angiogenesis.N6-甲基腺苷修饰在肿瘤血管生成中的作用。
Front Oncol. 2024 Dec 3;14:1467850. doi: 10.3389/fonc.2024.1467850. eCollection 2024.
6
Vessel co-option: a unique vascular-immune niche in liver cancer.血管共选择:肝癌中一种独特的血管免疫微环境
Front Oncol. 2024 Apr 26;14:1386772. doi: 10.3389/fonc.2024.1386772. eCollection 2024.
7
Vascular mimicry as a facilitator of melanoma brain metastasis.血管拟态作为黑色素瘤脑转移的促进因素。
Cell Mol Life Sci. 2024 Apr 18;81(1):188. doi: 10.1007/s00018-024-05217-z.
8
MicroRNA-204 Regulates Angiogenesis and Vasculogenic Mimicry in CD44+/CD24- Breast Cancer Stem-like Cells.微小RNA-204调控CD44+/CD24-乳腺癌干细胞样细胞中的血管生成和血管生成拟态
Noncoding RNA. 2024 Feb 9;10(1):14. doi: 10.3390/ncrna10010014.
9
Curcumin Inhibits Vasculogenic Mimicry Regulating ETS-1 in Renal Cell Carcinoma.姜黄素抑制血管生成拟态调控肾细胞癌中的 ETS-1。
Curr Cancer Drug Targets. 2024;24(10):1031-1046. doi: 10.2174/0115680096277126240102060617.
10
Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.血管生成及其生物标志物在肿瘤靶向治疗发展中的作用。
Stem Cells Int. 2024 Jan 4;2024:9077926. doi: 10.1155/2024/9077926. eCollection 2024.
利用无创影像学方法预测结直肠癌肝转移的组织病理学生长模式。
Ann Surg Oncol. 2019 Dec;26(13):4587-4598. doi: 10.1245/s10434-019-07910-x. Epub 2019 Oct 11.
4
Limitations of Anti-Angiogenic Treatment of Tumors.肿瘤抗血管生成治疗的局限性
Transl Oncol. 2019 Jul;12(7):981-986. doi: 10.1016/j.tranon.2019.04.022. Epub 2019 May 20.
5
Vessel co-option in cancer.血管生成拟态在癌症中的作用
Nat Rev Clin Oncol. 2019 Aug;16(8):469-493. doi: 10.1038/s41571-019-0181-9.
6
Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.实验和计算分析揭示了肿瘤血管选择的动力学和最佳治疗策略。
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2662-2671. doi: 10.1073/pnas.1818322116. Epub 2019 Jan 30.
7
Targeting Angiogenesis in Colorectal Carcinoma.靶向结直肠癌中的血管生成。
Drugs. 2019 Jan;79(1):63-74. doi: 10.1007/s40265-018-1037-9.
8
Anti-angiogenic therapy for high-grade glioma.高级别胶质瘤的抗血管生成治疗。
Cochrane Database Syst Rev. 2018 Nov 22;11(11):CD008218. doi: 10.1002/14651858.CD008218.pub4.
9
Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.胶质母细胞瘤内皮通过调节 PLXDC1 促进贝伐珠单抗诱导的浸润性生长。
Int J Cancer. 2019 Mar 15;144(6):1331-1344. doi: 10.1002/ijc.31983. Epub 2018 Dec 16.
10
CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.CXCR2 表达的肿瘤细胞驱动抗血管生成治疗耐药性脑胶质瘤中的血管拟态形成。
Neoplasia. 2018 Oct;20(10):1070-1082. doi: 10.1016/j.neo.2018.08.011.